Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NST-628 in Recurrent Grade 4 Glioma
NCT07784985Phase 1Not yet recruiting
- Sponsor
- Ivy Brain Tumor Center
- Start
- Oct 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nst-628 in glioma, sponsored by Ivy Brain Tumor Center. Primary endpoints: Percent Change of pERK Expression in Tumor Tissue and Incidence of Adverse Events as Assessed by CTCAE v5.0. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
nst-628
03
Conditions
glioma
Beyond the preview
Go deeper on NCT07784985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07784985.